 |
Welcome to Tocris |
View Basket | Checkout
| Log In
|
| Home | Products | Technical Support | Customer Support | Literature | Custom Synthesis |
|
Tocris in the News
TOCRIS BIOSCIENCE COMPLETES MANAGEMENT BUY OUT
11th January 2007 – Prominent life science company Tocris Bioscience (Bristol, UK) has today announced the successful completion of a $40 million management buy out (“MBO”) deal. Backed by the Royal Bank of Scotland, the MBO will provide Tocris with the ability and freedom to further develop its existing business areas and to offer additional products and services to its international client base. Tocris will continue to be led by existing directors Laurence Ede (Managing Director) and Andrew Birnie (Finance Director), together with Tony Kenny of Momentum Corporate Finance who joins the board as Chairman. Notably, Tocris’ managers have also taken significant equity stakes themselves, illustrative of the entire workforce’s commitment to the business. “The MBO represents the next major step in our plan to make Tocris the undisputed supplier of choice in the life science sector and ensures that as we grow, the Tocris brand will continue to be synonymous with great-value products of unparalleled quality and efficacy.” explained Laurence Ede. Andrew Birnie added “This deal gives us the opportunity to fully realise Tocris extraordinary potential and I look forward to working with the team to make that happen. Not only is this a tremendous result for the company, but also for all those who share our independent spirit and absolute dedication to life science.” The team was advised throughout by Momentum Corporate Finance LLP and Burges Salmon LLP and the MBO was concluded with the full support of the outgoing founder-shareholder group.
About Tocris Bioscience
Tocris Bioscience (www.tocris.com) is a leading supplier of high performance chemicals, peptides and antibodies, with customers in all of the worlds’ major pharmaceutical companies, universities and research institutes. The Company is committed to making new life science discoveries possible by providing the highest performing and most innovative range of research reagents.
Tocris Bioscience products are used by scientists carrying out non-clinical research in fields such as cancer, stroke, Alzheimer’s disease and obesity. The Company's catalogue of over 2000 reagents represents a unique collection of novel, exclusive and licensed research tools and is sent to more than 50,000 scientists worldwide annually. A major source of key signal transduction reagents and arguably the world leader in the supply of neuroscience reagents, the Company won the Queen’s Award for Enterprise (International Business) in 2002.
Tocris Bioscience is the trading name for the companies in the Tocris Cookson Group. Tocris Cookson Ltd is privately held and headquartered in Bristol, UK. Its US subsidiary, Tocris Cookson Inc, is located in St. Louis, Missouri, USA. There are approximately 60 employees in the Group worldwide, operating out of three sites in the UK and one in the US.
Search the Tocris product catalogue online.
Momentum Corporate FinanceMomentum Corporate Finance LLP (www.momentumcf.com) was formed in 2005 by partners, Tony Kenny and Rob Crews, both previously senior corporate financiers with PricewaterhouseCoopers. Tony Kenny led PwC’s corporate finance business in the West & Wales region and their technology corporate finance business in London. Momentum acts for entrepreneurial businesses, concentrating on mid-market transactions, mostly in the £5 million to £100 million range. The business is based in Bristol, UK, but also has offices in London’s Covent Garden and Park Avenue in New York. |
Exceptional Science and Great Value
Laurence Ede Managing Director Tocris Bioscience
It's no secret
that Tocris provides great value; tens of thousands of customers around the world are testament to that. But what is equally important about Tocris, and what keeps people using our products year after year, are the values that define the way we work. Commitment. Integrity. Empathy.
|